US 12,467,097 B2
DNA methylation marker for predicting recurrence of liver cancer, and use thereof
Young Joon Kim, Seoul (KR); Da Won Kim, Seoul (KR); Tae You Kim, Seoul (KR); Kwang Woong Lee, Seoul (KR); and Jeong Sil Ha, Seoul (KR)
Assigned to LEPIDYNE CO., LTD., Seoul (KR)
Appl. No. 17/434,675
Filed by LEPIDYNE CO., LTD., Seoul (KR)
PCT Filed Feb. 26, 2020, PCT No. PCT/KR2020/002727
§ 371(c)(1), (2) Date Aug. 27, 2021,
PCT Pub. No. WO2020/175903, PCT Pub. Date Sep. 3, 2020.
Claims priority of application No. 10-2019-0024379 (KR), filed on Feb. 28, 2019.
Prior Publication US 2023/0109129 A1, Apr. 6, 2023
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01)] 4 Claims
 
1. A method for predicting high risk of recurrence of liver cancer comprising:
(a) providing a kit comprising reagents capable of detecting methylation levels of at least two DNA methylation markers, wherein the DNA methylation markers are selected from SEQ ID Nos: 1, 2, 3, and 4
(b) isolating genomic DNA from a liver tissue sample derived from a subject;
(c) detecting, in the isolated genomic DNA, methylation levels of at least two DNA methylation markers by using the kit;
(d) determining that the methylation levels of the DNA methylation markers in the liver tissue sample are 50% or less compared to that of the methylation levels of the DNA methylation markers in normal liver tissues,
(e) predicting that the subject has a high risk of liver cancer recurrence; and
(f) treating the subject predicated to have a high risk of liver recurrence with chemotherapy, surgery, or radiation therapy.